Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Costa on the Background of the MASTER Trial in Newly Diagnosed Multiple Myeloma

August 1st 2023

Luciano J. Costa, MD, PhD, discusses the background of the phase 2 MASTER trial in newly diagnosed multiple myeloma.

Combination Strategies With Bispecifics in Multiple Myeloma

August 1st 2023

Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.

Bispecifics in Multiple Myeloma: Adverse Event Management

August 1st 2023

Expert perspectives on adverse event management in patients on bispecific therapy for multiply relapsed multiple myeloma.

Dr Mohty on Bispecific Antibodies in R/R Multiple Myeloma

July 28th 2023

Mohamad Mohty, MD, PhD, discusses unmet needs in patients with relapsed/refractory multiple myeloma and the rationale for investigating elranatamab monotherapy in this population in the phase 2 MagnetisMM-3 trial.

Dr Bal on Sequencing Considerations for BMCA- and GPRC5D-Targeted Agents in Multiple Myeloma

July 27th 2023

Susan Bal, MD, discusses questions remaining regarding sequencing of treatments in later lines for patients with relapsed/refractory multiple myeloma.

FDA Clears Investigational New Drug Application for TCR-NK Cell Therapy in Multiple Myeloma

July 26th 2023

The FDA has issued a ‘safe to proceed’ for the investigational new drug application enabling a phase 1 study evaluating NY-ESO-1 TCR/IL-15 NK, a first-in-class engineered T-cell receptor natural killer cell therapy for patients with relapsed/refractory multiple myeloma.

Dr Matous on the Future Directions of CAR T-Cell Therapy in Multiple Myeloma

July 25th 2023

Jeffrey V. Matous, MD, discusses future directions of CAR T-cell therapy in multiple myeloma, highlighting the potential promise of novel targets beyond BCMA.

Bispecifics in Multiple Myeloma: Dosing and Transition of Care

July 25th 2023

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment

July 25th 2023

Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.

Dr Munshi on the Background of the CARTITUDE-1 Trial in Multiple Myeloma

July 24th 2023

Nikhil C. Munshi, MD, discusses the background of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and highlights the specific patient population enrolled in the study.

Dr Patel on Safety Data and Biomarker Outcomes With Ide-Cel in High-Risk R/R Multiple Myeloma

July 21st 2023

Krina K. Patel, MD, MSc, discusses the safety profile of idecabtagene vicleucel in a subgroup of patients with high-risk, relapsed/refractory multiple myeloma, as well as findings with soluble BCMA levels from the phase 3 KarMMa-3 trial.

Teclistamab Snags Positive CHMP Opinion for Relapsed/Refractory Multiple Myeloma

July 21st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of a Type II variation for teclistamab in the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies.

CHMP Recommends Talquetamab Monotherapy for R/R Multiple Myeloma

July 21st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended conditional marketing authorization of talquetamab for use as a single agent in adult patients with relapsed or refractory multiple myeloma who have previously received at least 3 therapies.

Dr Munshi on Implications of Findings From the CARTITUDE-1 Trial of Cilta-Cel in Myeloma

July 20th 2023

Nikhil C. Munshi, MD, discusses the implications of the findings from the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and the CAR T-cell therapy’s subsequent FDA approval for use in this patient population.

Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy

July 18th 2023

Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.

Factors in Selecting Therapy at First Relapse in Multiple Myeloma

July 18th 2023

Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.

Dr Matous on Ongoing Multiple Myeloma Clinical Trials at Colorado Blood Cancer Institute

July 17th 2023

Jeffrey V. Matous, MD, discusses upcoming and ongoing clinical trials in multiple myeloma being conducted at the Colorado Blood Cancer Institute.

Dr Matous on the Benefit Derived from the IKEMA Trial in R/R Multiple Myeloma

July 14th 2023

Jeffrey V. Matous, MD, discusses the benefit derived from the phase 3 IKEMA trial in patients with relapsed/refractory multiple myeloma, highlighting the key factors to take into account when evaluating patients for relapsed/refractory disease within this treatment space.

Dr Matous on Barriers to CAR T-Cell Therapy Administration in Multiple Myeloma

July 13th 2023

Jeffrey V. Matous, MD, discusses potential strategies to overcome barriers to receiving CAR T-cell therapy for patients with multiple myeloma, and how the potential use of these agents in earlier lines could improve infusion wait times and rates of disease progression.

Multiple Myeloma Treatment Advances Promote a Future of Individualized Patient Care

July 11th 2023

Jeffrey V. Matous, MD, highlights takeaways from the phase 3 IKEMA trial and notes the benefits of administering CAR T-cell therapy in earlier lines, as evidenced in primary results from the phase 3 CARTITUDE-4 trial.